Cap. Omesoft
Capsule · Oral · 1000mg · 1 capsule
৳10
Cap.
Omesoft
Omega-3 Acid Ethyl Esters [Salmon Fish Oil]
— Pacific Pharmaceuticals Ltd.
1000mg
· 1 capsule
Presentation
Dose rules
No structured dose rules are linked to this brand yet.
Dose reference
Human
In hypertriglyceridaemia: it can be taken as a single dose of 4 capsules (4 gm) or 2 capsules (2 gm) twice daily.In previously myocardial infarction patients: It can be taken 1 capsule (1 gm ) daily with food. Patients should be placed on an appropriate lipid lowering diet before receiving Omega-3 Acid Ethyl Esters and should continue this diet during treatment.In joint inflammation associated with mild arthritis: The dose is 2.7 gm daily.In mood disorders & impulse control and age-related macular degeneration: The dose is 1 capsule (1 gm) per day. Or, as directed by the registered physician.
Clinical notes
Applications:
N/A
Indication Notes:
Omega-3 Acid Ethyl Esters is indicated as an adjunct to diet to reduce very high (>500mg/dl) triglyceride (TG) levels in adult patients and as an adjunct in secondary prevention in those who have had a myocardial infarction in the preceding 3 months. It is also indicated to help reduce the joint ... Read moreOmega-3 Acid Ethyl Esters is indicated as an adjunct to diet to reduce very high (>500mg/dl) triglyceride (TG) levels in adult patients and as an adjunct in secondary prevention in those who have had a myocardial infarction in the preceding 3 months. It is also indicated to help reduce the joint inflammation associated with mild arthritis, mood disorders & impulse control, age-related macular degeneration.
Avoid In:
N/A
Contraindication Notes:
It is contraindicated in patients who exhibit hypersensitivity to any component of this medication.
Omega-3-acid ethyl esters reduce triglyceride production by the liver but this mechanism is not well understood. Omega-3-acid ethyl esters inhibit acyl-CoA: 1,2-diacylglycerol acyltransferase, reducing triglyceride synthesis and increasing paroxysmal beta-oxidation, which increases fatty aside metabolism. Omega-3-acid ethyl esters also inhibit the release of fatty acids by competing for enzymes involved in the synthesis of triglycerides, increase triglyceride clearance by increasing the activity of lipoprotein lipase, and decrease production of VLDL-C.
Patients receiving treatment with both Omega-3-acid ethyl esters and anticoagulants should be monitored periodically.
Adverse events are rarely reported such as dyspepsia, nausea, constipation, gastritis, dizziness etc.
Omega-3-acid ethyl esters should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether it is excreted in human milk. Caution should be exercised when Omega-3-acid ethyl esters are administered to a lactating mother.
During therapy with omega-3-acid ethyl esters, LDL-C levels should be monitored and laboratory studies should be performed periodically to measure the patient's TG levels.